SUBSCRIBE
SUBSCRIBE

Teva Pharmaceutical Industries Limited Announces Pricing of $2.5 Billion of Senior Notes

June 16, 2010 | 
1 min read
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) (“Teva”) announced today that it successfully priced the offering, by its special purpose finance subsidiaries, of a debt offering in three tranches:
Asia
MORE ON THIS TOPIC
Business people shaking hand in China.
China
Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
September 24, 2026
 · 
1 min read
 · 
Tristan Manalac
Microscope icon. Molecule and communication background. Connected lines with dots.
Deals
Novartis bets up to $900M for radioligand therapy from China’s BoomRay
September 23, 2026
 · 
2 min read
 · 
Tristan Manalac
China flag on bar chart concept with increasing values, economic recovery and business improving after crisis and other catastrophe as economy and businesses reopen again
Manufacturing
Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
September 21, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Symbolic image: Tablets, US Dollar and China - Dependence on the Chinese pharmaceutical industry
China
China plans to transform biotech sector into $522B powerhouse by 2030
September 18, 2026
 · 
2 min read
 · 
Annalee Armstrong